Co-Authors
This is a "connection" page, showing publications co-authored by ARA A VAPORCIYAN and APAR PATAER.
Connection Strength
1.490
-
Major Pathologic Response and Prognostic Score Predict Survival in Patients With Lung Cancer Receiving Neoadjuvant Chemotherapy. JTO Clin Res Rep. 2022 Nov; 3(11):100420.
Score: 0.221
-
Evaluation of Pathologic Response in Lymph Nodes of Patients With Lung Cancer Receiving Neoadjuvant Chemotherapy. J Thorac Oncol. 2021 08; 16(8):1289-1297.
Score: 0.200
-
Therapeutic targeting of the PI4K2A/PKR lysosome network is critical for misfolded protein clearance and survival in cancer cells. Oncogene. 2020 01; 39(4):801-813.
Score: 0.180
-
Major pathologic response and RAD51 predict survival in lung cancer patients receiving neoadjuvant chemotherapy. Cancer Med. 2018 06; 7(6):2405-2414.
Score: 0.163
-
Histopathologic response criteria predict survival of patients with resected lung cancer after neoadjuvant chemotherapy. J Thorac Oncol. 2012 May; 7(5):825-32.
Score: 0.108
-
Surgical outcomes after chemotherapy plus nivolumab and chemotherapy plus nivolumab and ipilimumab in patients with non-small cell lung cancer. J Thorac Cardiovasc Surg. 2024 Apr; 167(4):1444-1453.e4.
Score: 0.059
-
Neoadjuvant chemotherapy plus nivolumab with or without ipilimumab in operable non-small cell lung cancer: the phase 2 platform NEOSTAR trial. Nat Med. 2023 03; 29(3):593-604.
Score: 0.057
-
Epstein Barr virus-positive B-cell lymphoma is highly vulnerable to MDM2 inhibitors in vivo. Blood Adv. 2022 02 08; 6(3):891-901.
Score: 0.053
-
Surgical outcomes after neoadjuvant nivolumab or nivolumab with ipilimumab in patients with non-small cell lung cancer. J Thorac Cardiovasc Surg. 2022 11; 164(5):1327-1337.
Score: 0.053
-
Nodal immune flare mimics nodal disease progression following neoadjuvant immune checkpoint inhibitors in non-small cell lung cancer. Nat Commun. 2021 08 19; 12(1):5045.
Score: 0.051
-
Neoadjuvant nivolumab or nivolumab plus ipilimumab in operable non-small cell lung cancer: the phase 2 randomized NEOSTAR trial. Nat Med. 2021 03; 27(3):504-514.
Score: 0.049
-
Pathological nodal disease defines survival outcomes in patients with lung cancer with tumour major pathological response following neoadjuvant chemotherapy. Eur J Cardiothorac Surg. 2021 01 04; 59(1):100-108.
Score: 0.049
-
Agreement on Major Pathological Response in NSCLC Patients Receiving Neoadjuvant Chemotherapy. Clin Lung Cancer. 2020 07; 21(4):341-348.
Score: 0.046
-
Tumor characteristics associated with engraftment of patient-derived non-small cell lung cancer xenografts in immunocompromised mice. Cancer. 2019 11 01; 125(21):3738-3748.
Score: 0.044
-
Glutathione reductase (GSR) gene deletion and chromosome 8 aneuploidy in primary lung cancers detected by fluorescence in situ hybridization. Am J Cancer Res. 2019; 9(6):1201-1211.
Score: 0.044
-
Effect of neoadjuvant chemotherapy on the immune microenvironment in non-small cell lung carcinomas as determined by multiplex immunofluorescence and image analysis approaches. J Immunother Cancer. 2018 06 06; 6(1):48.
Score: 0.041
-
Induction Cisplatin Docetaxel Followed by Surgery and Erlotinib in Non-Small Cell Lung Cancer. Ann Thorac Surg. 2018 Feb; 105(2):418-424.
Score: 0.040
-
Gene mutations in primary tumors and corresponding patient-derived xenografts derived from non-small cell lung cancer. Cancer Lett. 2015 Feb 01; 357(1):179-185.
Score: 0.032